Union européenne - français - EMA (European Medicines Agency)

recordati netherlands b.v. - siltuximab - hyperplasie des ganglions lymphatiques géants - immunosuppresseurs - sylvant est indiqué pour le traitement des patients adultes atteints de la maladie de castleman multicentrique (mcm qui sont négatifs pour le virus de l'immunodéficience humaine (vih) et l'herpèsvirus humain 8 (hhv-8) négatif.

Canada - français - Health Canada

eusa pharma (uk) limited - siltuximab - poudre pour solution - 100mg - siltuximab 100mg - immunosuppressive agents

Canada - français - Health Canada

eusa pharma (uk) limited - siltuximab - poudre pour solution - 400mg - siltuximab 400mg - immunosuppressive agents

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

medius ag - siltuximabum - poudre pour solution à diluer pour perfusion - praeparatio cryodesiccata: siltuximabum 110 mg, saccharum, histidini hydrochloridum monohydricum aut histidinum, polysorbatum 80, pro vitro. - castleman-krankheit - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

medius ag - siltuximabum - poudre pour solution à diluer pour perfusion - praeparatio cryodesiccata: siltuximabum 420 mg, saccharum, histidini hydrochloridum monohydricum aut histidinum, polysorbatum 80, pro vitro. - castleman-krankheit - biotechnologika

Canada - français - Health Canada

gilead sciences canada inc - axicabtagene ciloleucel - suspension - 200000000cellules - axicabtagene ciloleucel 200000000cellules - antineoplastic agents

Canada - français - Health Canada

pfizer canada ulc - elranatamab - solution - 44mg - elranatamab 44mg

Canada - français - Health Canada

pfizer canada ulc - elranatamab - solution - 76mg - elranatamab 76mg

Union européenne - français - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - agents antinéoplasiques - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.